-$0.13 EPS Expected for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) This Quarter

Analysts expect that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLIGet Rating) will report ($0.13) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics reported earnings of ($0.19) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 31.6%. The firm is expected to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full year earnings of ($0.60) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($0.60) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) last posted its quarterly earnings results on Monday, March 28th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. During the same quarter last year, the firm earned ($0.37) earnings per share.

Separately, StockNews.com started coverage on shares of Brainstorm Cell Therapeutics in a research report on Wednesday. They set a “hold” rating for the company.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Brainstorm Cell Therapeutics by 0.7% during the fourth quarter. BlackRock Inc. now owns 472,476 shares of the biotechnology company’s stock worth $1,890,000 after acquiring an additional 3,509 shares in the last quarter. Wells Fargo & Company MN grew its position in Brainstorm Cell Therapeutics by 40.8% in the 4th quarter. Wells Fargo & Company MN now owns 18,558 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 5,376 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Brainstorm Cell Therapeutics in the 4th quarter worth about $40,000. Geode Capital Management LLC grew its position in Brainstorm Cell Therapeutics by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 275,750 shares of the biotechnology company’s stock worth $909,000 after purchasing an additional 10,612 shares in the last quarter. Finally, S.C. Financial Services Inc. bought a new stake in Brainstorm Cell Therapeutics in the 4th quarter worth about $52,000. 14.47% of the stock is owned by institutional investors.

Shares of NASDAQ BCLI opened at $3.09 on Wednesday. The company has a 50-day moving average price of $3.22 and a 200-day moving average price of $3.29. The stock has a market capitalization of $112.74 million, a P/E ratio of -4.54 and a beta of -0.04. Brainstorm Cell Therapeutics has a 1 year low of $2.75 and a 1 year high of $4.46.

Brainstorm Cell Therapeutics Company Profile (Get Rating)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Featured Stories

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.